Russian Journal of Child NeurologyRussian Journal of Child NeurologyРусский журнал детской неврологии2073-88032412-9178Publishing House ABV Press2110.17650/2073-8803-2014-9-2-42-49REVIEWS AND LECTURESОБЗОРЫ И ЛЕКЦИИUSE OF ZONISAMIDE (ZONEGRAN) IN THE TREATMENT OF EPILEPSY: EMPHASIS ON MONOTHERAPY OF FOCAL SEIZURES (A REVIEW OF FOREIGN LITERATURE)Применение зонисамида (Зонегран) в лечении эпилепсии: акцент на монотерапию фокальных приступов (обзор зарубежной литературы)PylaevaO. A.ПылаеваО. А.
Russian Federation
olgapylaeva@yandex.ruMukhinK. Yu.МухинК. Ю.
Russian Federation
Saint Lukа’s Institute of Child Neurology and Epilepsy, MoscowООО «Институт детской неврологии и эпилепсии им. Святителя Луки», Москва150420149242491804201518042015Copyright ©; 2014, ABV-PressCopyright ©; 2014, АБВ-пресс2014ABV-PressАБВ-прессhttps://rjdn.abvpress.ru/jour/about/editorialPolicieshttps://rjdn.abvpress.ru/jour/article/view/21

Despite a considerable advance made in epileptology, resistant epilepsies are about 30 % among all epilepsy types. The paper reviews the current literature dealing with the efficacy and safety of the new antiepileptic drug zonisamide (Zonegran) in the treatment of epilepsy. It describes the mechanism of action, pharmacokinetics, efficacy, and tolerability of zonisamide in resistant epilepsy. The authors focus their attention on recent trials of zonisamide used in monotherapy.

Несмотря на значительные успехи, достигнутые в эпилептологии, резистентные эпилепсии составляют примерно 30 % среди всех форм эпилепсии. Представлен обзор современной литературы, посвященный эффективности и безопасности нового антиэпилептического препарата зонисамид (Зонегран®) в лечении эпилепсии. Описаны механизм действия, особенности фармакокинетики, эффективность и переносимость зонисамида при резистентной фокальной эпилепсии. Авторы акцентируют внимание на современных исследованиях применения зонисамида в монотерапии.

epilepsyzonisamidefocal seizuresmonotherapyefficacytolerabilityэпилепсиязонисамидфокальные приступымонотерапияэффективностьпереносимость1. Пылаева О.А., Мухин К.Ю. Применение нового антиэпилептического препарата – зонегран (зонисамид) – в лечении эпилепсии (обзор литературы). Рус журн дет неврол 2012;7(2):13–34.Пылаева О.А., Мухин К.Ю. Применение нового антиэпилептического препарата – зонегран (зонисамид) – в лечении эпилепсии (обзор литературы). Рус журн дет неврол 2012;7(2):13–34.2. Afra P., Adamolekun B. Update on once-daily zonisamide monotherapy in partial seizures. Neuropsychiatr Dis Treat 2014;10:493–8.Afra P., Adamolekun B. Update on once-daily zonisamide monotherapy in partial seizures. Neuropsychiatr Dis Treat 2014;10:493–8.3. Arzimanoglou A., Rahbani A. Zonisamide for the treatment of epilepsy. Expert Rev Neurother 2006;6(9):1283–92.Arzimanoglou A., Rahbani A. Zonisamide for the treatment of epilepsy. Expert Rev Neurother 2006;6(9):1283–92.4. Baulac M. Introduction to zonisamide. Epilepsy Res 2006;68 Suppl 2:S3–9.Baulac M. Introduction to zonisamide. Epilepsy Res 2006;68 Suppl 2:S3–9.5. Baulac M., Brodie M.J., Patten A. et al. Efficacy and tolerability of zonisamide versus controlled-release carbamazepine for newly diagnosed partial epilepsy: a phase 3, randomised, double-blind, non-inferiority trial. Lancet Neurol 2012;11(7):579–88.Baulac M., Brodie M.J., Patten A. et al. Efficacy and tolerability of zonisamide versus controlled-release carbamazepine for newly diagnosed partial epilepsy: a phase 3, randomised, double-blind, non-inferiority trial. Lancet Neurol 2012;11(7):579–88.6. Baulac M., Leppik I.E. Efficacy and safety of adjunctive zonisamide therapy for refractory partial seizures. Epilepsy Res 2007;75(2–3):75–83.Baulac M., Leppik I.E. Efficacy and safety of adjunctive zonisamide therapy for refractory partial seizures. Epilepsy Res 2007;75(2–3):75–83.7. Biton V. Clinical pharmacology and mechanism of action of zonisamide. Clin Neuropharmacol 2007;30(4):230–40.Biton V. Clinical pharmacology and mechanism of action of zonisamide. Clin Neuropharmacol 2007;30(4):230–40.8. Biton V. Zonisamide: newer antiepileptic agent with multiple mechanisms of action. Expert Rev Neurother 2004;4(6):935–43.Biton V. Zonisamide: newer antiepileptic agent with multiple mechanisms of action. Expert Rev Neurother 2004;4(6):935–43.9. Brodie M.J. Zonisamide as adjunctive therapy for refractory partial seizures. Epilepsy Res 2006;68 Suppl 2:S11–6.Brodie M.J. Zonisamide as adjunctive therapy for refractory partial seizures. Epilepsy Res 2006;68 Suppl 2:S11–6.10. Brodie M.J. Zonisamide clinical trials: European experience. Seizure 2004;13 Suppl 1: S66–70.Brodie M.J. Zonisamide clinical trials: European experience. Seizure 2004;13 Suppl 1: S66–70.11. Brodie M.J., Duncan R., Vespignani H. et al. Dose-dependent safety and efficacy of zonisamide: a randomized, double-blind, placebo-controlled study in patients with refractory partial seizures. Epilepsia 2005;46(1):31–41.Brodie M.J., Duncan R., Vespignani H. et al. Dose-dependent safety and efficacy of zonisamide: a randomized, double-blind, placebo-controlled study in patients with refractory partial seizures. Epilepsia 2005;46(1):31–41.12. Chadwick D.W., Marson A.G. Zonisamide add-on for drug-resistant partial epilepsy. Cochrane Database Syst Rev 2002;(2):CD001416.Chadwick D.W., Marson A.G. Zonisamide add-on for drug-resistant partial epilepsy. Cochrane Database Syst Rev 2002;(2):CD001416.13. Elger C.E., Schmidt D. Modern management of epilepsy: а practical approach. Epilepsy Behavior 2008;12(4):501–39.Elger C.E., Schmidt D. Modern management of epilepsy: а practical approach. Epilepsy Behavior 2008;12(4):501–39.14. Farooq M.U., Moore P.W., Bhatt A. et al. Therapeutic role of zonisamide in neuropsychiatric disorders. Mini Rev Med Chem 2008;8(10):968–75.Farooq M.U., Moore P.W., Bhatt A. et al. Therapeutic role of zonisamide in neuropsychiatric disorders. Mini Rev Med Chem 2008;8(10):968–75.15. Faught E. Review of United States and European clinical trials of zonisamide in the treatment of refractory partial-onset seizures. Seizure 2004;13 Suppl 1:S59–65.Faught E. Review of United States and European clinical trials of zonisamide in the treatment of refractory partial-onset seizures. Seizure 2004;13 Suppl 1:S59–65.16. Frampton J.E., Scott L.J. Zonisamide: a review of its use in the management of partial seizures in epilepsy. CNS Drugs 2005;19(4):347–67.Frampton J.E., Scott L.J. Zonisamide: a review of its use in the management of partial seizures in epilepsy. CNS Drugs 2005;19(4):347–67.17. Fujii T., Furukama H., Matsumoto K. et al. Dainippon Pharmaceutical Co, Ltd, Developmental Laboratories. Data on file, 1989. Japanese.Fujii T., Furukama H., Matsumoto K. et al. Dainippon Pharmaceutical Co, Ltd, Developmental Laboratories. Data on file, 1989. Japanese.18. Fukushima K., Seino M. A long-term follow-up of zonisamide monotherapy. Epilepsia 2006;47(11):1860–4.Fukushima K., Seino M. A long-term follow-up of zonisamide monotherapy. Epilepsia 2006;47(11):1860–4.19. Gadde K.M., Franciscy D.M., Wagner H.R. 2nd, Krishnan K.R. Zonisamide for weight loss in obese adults: a randomized controlled trial. JAMA 2003;289(14):1820–5.Gadde K.M., Franciscy D.M., Wagner H.R. 2nd, Krishnan K.R. Zonisamide for weight loss in obese adults: a randomized controlled trial. JAMA 2003;289(14):1820–5.20. Glauser T., Ben-Menachem E., Bourgeois B. et al. Updated ILAE evidence review of antiepileptic drug efficacy and effectiveness as initial monotherapy for epileptic seizures and syndromes. Epilepsia 2013;54(3):551–63.Glauser T., Ben-Menachem E., Bourgeois B. et al. Updated ILAE evidence review of antiepileptic drug efficacy and effectiveness as initial monotherapy for epileptic seizures and syndromes. Epilepsia 2013;54(3):551–63.21. Helmstaedter C., Stefan H., Witt J.A. Quality of life in patients with partial-onset seizures under adjunctive therapy with zonisamide: results from a prospective noninterventional surveillance study. Epileptic Disord 2011;13(3)263–76.Helmstaedter C., Stefan H., Witt J.A. Quality of life in patients with partial-onset seizures under adjunctive therapy with zonisamide: results from a prospective noninterventional surveillance study. Epileptic Disord 2011;13(3)263–76.22. Janszky J. Role of zonisamide in treating epilepsy, Parkinson disorders and other neurological diseases. Ideggyogy Sz 2009;62(11–12):383–9.Janszky J. Role of zonisamide in treating epilepsy, Parkinson disorders and other neurological diseases. Ideggyogy Sz 2009;62(11–12):383–9.23. Kelemen A., Rasonyl G., Neuwirth M. et al. Our clinical experience with zonisamide in resistant generalized epilepsy syndromes. Ideggyogy Sz 2011;64(5–6):187–92.Kelemen A., Rasonyl G., Neuwirth M. et al. Our clinical experience with zonisamide in resistant generalized epilepsy syndromes. Ideggyogy Sz 2011;64(5–6):187–92.24. Kim H.L., Aldridge J., Rho J.M. Clinical experience with zonisamide monotherapy and adjunctive therapy in children with epilepsy at a tertiary care referral center. J Child Neurol 2005;20(3):212–19.Kim H.L., Aldridge J., Rho J.M. Clinical experience with zonisamide monotherapy and adjunctive therapy in children with epilepsy at a tertiary care referral center. J Child Neurol 2005;20(3):212–19.25. Kothare S.V., Kaleyias J. Zonisamide: review of pharmacology, clinical efficacy, tolerability, and safety. Expert Opin Drug Metab Toxicol 2008;4(4):493–506.Kothare S.V., Kaleyias J. Zonisamide: review of pharmacology, clinical efficacy, tolerability, and safety. Expert Opin Drug Metab Toxicol 2008;4(4):493–506.26. Kothare S.V., Kaleyias J., Mostofi N. et al. Efficacy and safety of zonisamide monotherapy in a cohort of children with epilepsy. Pediatric Neurol 2006;34(5):351–4.Kothare S.V., Kaleyias J., Mostofi N. et al. Efficacy and safety of zonisamide monotherapy in a cohort of children with epilepsy. Pediatric Neurol 2006;34(5):351–4.27. Kwak S.E., Kim J.E., Kim D.S. et al. Differential effects of vigabatrin and zonisamide on the neuropeptide Y system in the hippocampus of seizure prone gerbil. Neuropeptides 2005;39(5):507–13.Kwak S.E., Kim J.E., Kim D.S. et al. Differential effects of vigabatrin and zonisamide on the neuropeptide Y system in the hippocampus of seizure prone gerbil. Neuropeptides 2005;39(5):507–13.28. Kwan P., Brodie M.J. Early identification of refractory epilepsy. N Engl J Med 2000;342(5):314–9.Kwan P., Brodie M.J. Early identification of refractory epilepsy. N Engl J Med 2000;342(5):314–9.29. Kwan P., Brodie M.J. Epilepsy after the first drug fails: substitution or add-on? Seizure 2000;9(7):464–8.Kwan P., Brodie M.J. Epilepsy after the first drug fails: substitution or add-on? Seizure 2000;9(7):464–8.30. Kwan P., Brodie M.J. Refractory epilepsy: mechanisms and solutions. Expert Rev Neurother 2006;6(3):397–406.Kwan P., Brodie M.J. Refractory epilepsy: mechanisms and solutions. Expert Rev Neurother 2006;6(3):397–406.31. Leppik I.E. Practical prescribing and longterm efficacy and safety of zonisamide. Epilepsy Res 2006;68 Suppl 2:S17–24.Leppik I.E. Practical prescribing and longterm efficacy and safety of zonisamide. Epilepsy Res 2006;68 Suppl 2:S17–24.32. Leppik I.E. Zonisamide: chemistry, mechanism of action, and pharmacokinetics. Seizure 2004;13 Suppl 1:S5–9.Leppik I.E. Zonisamide: chemistry, mechanism of action, and pharmacokinetics. Seizure 2004;13 Suppl 1:S5–9.33. Lu Y., Xiao Z., Yu W. et al. Efficacy and safety of adjunctive zonisamide in adult patients with refractory partial-onset epilepsy: a randomized, double-blind, placebocontrolled trial. Clin Drug Investig 2011;31(4):221–9.Lu Y., Xiao Z., Yu W. et al. Efficacy and safety of adjunctive zonisamide in adult patients with refractory partial-onset epilepsy: a randomized, double-blind, placebocontrolled trial. Clin Drug Investig 2011;31(4):221–9.34. Newmark M.E., Dubinsky S. Zonisamide monotherapy in multi-group clinic. Seizure 2004;13(4):223–25.Newmark M.E., Dubinsky S. Zonisamide monotherapy in multi-group clinic. Seizure 2004;13(4):223–25.35. Ohtahara S. Zonisamide in the management of epilepsy – Japanese experience. Epilepsy Res 2006;68 Suppl 2: S25–33.Ohtahara S. Zonisamide in the management of epilepsy – Japanese experience. Epilepsy Res 2006;68 Suppl 2: S25–33.36. Ohtahara S., Yamatogi Y. Safety of zonisamide therapy: prospective follow-up survey. Seizure 2004;13 Suppl 1:S50–5.Ohtahara S., Yamatogi Y. Safety of zonisamide therapy: prospective follow-up survey. Seizure 2004;13 Suppl 1:S50–5.37. Park S.P., Kim S.Y., Hwang Y.H. et al. Long term efficacy and safety of zonisamide monotherapy in epilepsy patients. J Clin Neurol 2007;3(4):175–80.Park S.P., Kim S.Y., Hwang Y.H. et al. Long term efficacy and safety of zonisamide monotherapy in epilepsy patients. J Clin Neurol 2007;3(4):175–80.38. Seino M. Review of zonisamide development in Japan. Seizure 2004;13 Suppl 1: S2–4.Seino M. Review of zonisamide development in Japan. Seizure 2004;13 Suppl 1: S2–4.39. Seki T., Kumagai N., Maezawa M. Effects of zonisamide monotherapy in children with epilepsy. Seizure 2004;13 Suppl 1:S26–32.Seki T., Kumagai N., Maezawa M. Effects of zonisamide monotherapy in children with epilepsy. Seizure 2004;13 Suppl 1:S26–32.40. Sobieszek G., Borowicz K.K., Kimber-Trojnar Z. et al. Zonisamide: a new antiepileptic drug. Pol J Pharmacol 2003;55(5):683–9.Sobieszek G., Borowicz K.K., Kimber-Trojnar Z. et al. Zonisamide: a new antiepileptic drug. Pol J Pharmacol 2003;55(5):683–9.41. Tosches W.A., Tisdell J. Long-term efficacy and safety of monotherapy and adjunctive therapy with zonisamide. Epilepsy Behav 2006;8(3):522–6.Tosches W.A., Tisdell J. Long-term efficacy and safety of monotherapy and adjunctive therapy with zonisamide. Epilepsy Behav 2006;8(3):522–6.42. Ueda Y., Doi T., Tokumaru J., Willmore L.J. Effect of zonisamide on molecular regulation of glutamate and GABA transporter proteins during epileptogenesis in rats with hippocampal seizures. Brain Res Mol Brain Res 2003;116(1–2):1–6.Ueda Y., Doi T., Tokumaru J., Willmore L.J. Effect of zonisamide on molecular regulation of glutamate and GABA transporter proteins during epileptogenesis in rats with hippocampal seizures. Brain Res Mol Brain Res 2003;116(1–2):1–6.43. Wilfong A.A. Zonisamide monotherapy for epilepsy in children and young adults. Pediatr Neurol 2005;32(2):77–80.Wilfong A.A. Zonisamide monotherapy for epilepsy in children and young adults. Pediatr Neurol 2005;32(2):77–80.44. Wilfong A.A., Willmore L.J. Zonisamide – a review of experience and use in partial seizures. Neuropsychiatr Dis Treat 2006;2(3):269–80.Wilfong A.A., Willmore L.J. Zonisamide – a review of experience and use in partial seizures. Neuropsychiatr Dis Treat 2006;2(3):269–80.45. Yamauchi T., Aikawa H. Efficacy of zonisamide: our experience. Seizure 2004; 13 Suppl 1:S41–8.Yamauchi T., Aikawa H. Efficacy of zonisamide: our experience. Seizure 2004; 13 Suppl 1:S41–8.46. Zaccara G., Specchio L.M. Long-term safety and effectiveness of zonisamide in the treatment of epilepsy: a review of the literature. Neuropsychiatr Dis Treat 2009;5:249–59.Zaccara G., Specchio L.M. Long-term safety and effectiveness of zonisamide in the treatment of epilepsy: a review of the literature. Neuropsychiatr Dis Treat 2009;5:249–59.47. Zaccara G., Tramacere L., Cincotta M. Drug safety evaluation of zonisamide for the treatment of epilepsy. Expert Opin Drug Saf 2011;10(4):623–31.Zaccara G., Tramacere L., Cincotta M. Drug safety evaluation of zonisamide for the treatment of epilepsy. Expert Opin Drug Saf 2011;10(4):623–31.48. Zareba G. Zonisamide: review of its use in epilepsy therapy. Drugs Today (Barc) 2005;41(9):589–97.Zareba G. Zonisamide: review of its use in epilepsy therapy. Drugs Today (Barc) 2005;41(9):589–97.